- 1、本文档共7页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
Ningbo Shanshan Co. Ltd deteriorating Suit
PAGE \* MERGEFORMAT 7
Ningbo Shanshan Co. Ltd deteriorating Suit
Firs Limited Liability Company’s performance please? Just fine for. Really? You might say: uncertain. This reveals the internal Shanshan Co., Ltd., a company - Ningbo Shanshan Co., Ltd. Suit on performance.
A, listed before the Firs: performance excellence
Shanshangufen company is listed in 1996. Prior to listing, the company there is only one of the leading products: suits. At that time the company’s performance is very good. Here is a group of accounting firms through the Dahua Certified Public Accountants (Ma Chongxia, Zhu order, January 18, 1996), Ningbo Municipal Asset Assessment Center (Legal Representative: Wang Xiangdong, the project is responsible for: Sun Bai, 1995 August 15 days) and Ningbo Municipal Finance Bureau (September 10, 1995), three identified a set of data. Obtained after finishing the following Table 1 and Table 2.
Project 199,319,941,995 annual growth rate of main business revenue 14903.517862.928033.937.15% Notes when the company main suit, there is no other product 3363.54208.75031.622.30% Operating Profit accounting system was different from now. Operating Profit = total profit of other profit = total profit of 3298.74319.75010.523.25% pre-tax profit after-tax profit 2803.22909.34165.221.90%
To create a large profit, the company spent on the total capital and total capital payments? After the above three bodies confirmed June 30, 1995, the company’s main asset indicators are as follows.
Item Total current assets Fixed assets Total assets Liabilities book value of net assets * 2,264,561,172,966,220,131 9531 evaluation and verification of assets 22687 7,999,336,812,013,113,550 net / evaluation and verification of assets 18.12% 52.07% 12.37% - 30.74% Main / evaluation and verification of assets 1.23 3.50 0.83 - 2.07
* Is equivalent to the current equity.
Two views:
1. Shanshan Co., Ltd. for three consecutive years prior to listing, profits, main business incom
您可能关注的文档
- NFB and ICAM1 in human coronary atherosclerotic plaque expression and disease progression and.doc
- NFB and its related inflammatory factors induced by cold preservation injury in liver transplantation mechanism.doc
- NFB and open abdominal wound and seawater immersion in rats the relationship between systemic inflammatory response syndrome.doc
- NFB inhibitor on neutrophil apoptosis.doc
- NF-KB expression in colon cancer and the relationship between.doc
- NFB signal pathway and secondary injury in acute spinal cord injury research progress.doc
- NFκBp65 and in ICAM1 expression in thyroid tumors and correlation analysis.doc
- NF-κB signaling pathway in the treatment of the role of inflammatory enteritis.doc
- NF-κB signaling pathway in the treatment of the role of inflammatory enteritis_0.doc
- NGC strain of dengue virus type 2 partial sequence of E gene expression in the original nuclear protein.doc
- 2024年头灯资金筹措计划书代可行性研究报告.docx
- 2024年澳代巴豆酸乙酯资金需求报告代可行性研究报告.docx
- 2024年水污染防治设备资金筹措计划书代可行性研究报告.docx
- 2024年纸卷包装输送系统资金申请报告代可行性研究报告.docx
- 2024年湿疹药物资金申请报告代可行性研究报告.docx
- 2024年家用通风电器具资金筹措计划书代可行性研究报告.docx
- 2024年数字模拟混合输出仪表通讯模板资金申请报告代可行性研究报告.docx
- 2024年计算器及货币专用设备资金需求报告代可行性研究报告.docx
- 2024年手工制纸及纸板项目投资申请报告代可行性研究报告.docx
- 2024年抗生素类药物资金筹措计划书代可行性研究报告.docx
文档评论(0)